VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 800 shares, a decline of 96.4% from the November 30th total of 22,500 shares. Based on an average daily trading volume, of 7,800 shares, the days-to-cover ratio is presently 0.1 days.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ:BBH traded down $0.28 during mid-day trading on Thursday, reaching $158.68. 8,887 shares of the company were exchanged, compared to its average volume of 7,306. VanEck Biotech ETF has a 1 year low of $151.35 and a 1 year high of $183.64. The firm’s 50-day simple moving average is $166.96 and its 200 day simple moving average is $172.63.

VanEck Biotech ETF Announces Dividend

The firm also recently disclosed a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were paid a $1.2517 dividend. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Investors Weigh In On VanEck Biotech ETF

Several large investors have recently added to or reduced their stakes in BBH. International Assets Investment Management LLC grew its position in shares of VanEck Biotech ETF by 10,376,390.9% during the third quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock worth $202,475,000 after buying an additional 1,141,403 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of VanEck Biotech ETF by 401.7% in the 3rd quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock valued at $1,481,000 after purchasing an additional 6,684 shares in the last quarter. Atlas Capital Advisors LLC purchased a new stake in shares of VanEck Biotech ETF during the 2nd quarter worth $960,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of VanEck Biotech ETF by 5.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock worth $4,096,000 after purchasing an additional 1,334 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in VanEck Biotech ETF in the third quarter valued at $166,000. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.